<DOC>
	<DOCNO>NCT00125983</DOCNO>
	<brief_summary>The purpose study examine drug interaction protease inhibitor ( PI ) -based regimen include lopinavir/ritonavir ( LPV/r ) two form contraceptive medication HIV infect woman .</brief_summary>
	<brief_title>Drug Interactions Between Lopinavir/Ritonavir Oral Patch Contraceptives HIV Infected Women</brief_title>
	<detailed_description>Both PIs oral contraceptive metabolize pathway , significantly decrease effectiveness oral contraceptive limit contraceptive choice available HIV infect woman . More effective hormonal contraceptive method necessary preventing unintended pregnancy woman take highly active antiretroviral therapy ( HAART ) . Ortho Evra contraceptive patch approve FDA 2001 ; use transdermal contraceptive system , high rate compliance associate use , compare oral contraceptive . Because Ortho Evra administer contraceptive patch worn skin , may bypass metabolic pathway common PIs oral contraceptive , make viable contraceptive option HIV infect woman PI-based regimen . The purpose study examine interaction PI-based regimen contain LPV/r two form contraceptive medication , Ortho Evra oral contraceptive , Ortho Novum ( ON 1/35 ) , HIV infect woman . Participants enrol study 6 week assign one two study arm , depend HAART regimen study entry . Participants arm also stratify age . Arm A participant receive 400 mg/100 mg LPV/r twice daily along two nucleoside reverse transcriptase inhibitor ( NRTIs ) . Arm B participant receive regimen contain NRTIs HAART . HAART provide study . All patient receive single dose ON 1/35 Day 1 start Ortho Evra contraceptive patch Day 3 . A physical exam , pap smear , pregnancy test , viral load test , CD4 CD8 count , blood collection occur study entry Day 24 . Pharmacokinetic analysis occur Days 1 3 , 17 19 , 24 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Ortho Evra</mesh_term>
	<mesh_term>Norinyl</mesh_term>
	<mesh_term>Norethindrone acetate , ethinyl estradiol , ferrous fumarate drug combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<criteria>Inclusion Criteria All Participants : HIV infect CD4 count 200 cells/mm3 within 45 day study entry HIV1 RNA viral load le 55,000 copies/ml within 45 day study entry Parent guardian willing provide inform consent Negative pregnancy test within 45 day study entry Willing use acceptable form contraception Agrees change current smoking nonsmoking habit Agrees consume caffeine Day 1 , Days 17 19 , Day 24 last blood sample day drawn Agrees consume alcohol within 48 hour PK sample period Patients methadone maintenance therapy stable methadone dose least 60 day prior study entry continue maintenance therapy throughout study Inclusion Criteria Arm A Participants : Have take LPV/r least 60 consecutive day prior study entry take dose twice daily least 14 day prior study entry . Women switch capsule formulation LPV/r new tablet formulation 200mg/50 mg LPV/r must take twicedaily dos formulation , total daily dose 800 mg/200 mg LPV/r , least 7 day prior study entry . Inclusion Criteria Arm B Participants : Have take currently take PI nonnucleoside reverse transcriptase inhibitor ( NNRTI ) base regimen least 30 day prior study entry , plan start PIs NNRTIs 6week study period . Women HAART least 30 day prior study entry also eligible . For patient receive HAART , documentation counsel benefit HIV treatment within 90 day study entry elect initiate therapy Exclusion Criteria All Participants : Use systemic hormonal therapy contain estrogen , progestin , anabolic steroid ( e.g. , estrogen , progesterone , oral contraceptive , Mirena [ levonorgestrol ] intrauterine device [ IUD ] , Progestasert [ progesterone ] IUD ) within 60 day study entry Anabolic therapy ( nandrolone decanoate megestrol ) within 60 day study entry Systemic glucocorticoid within 14 day study entry Certain medical condition . More information criterion find protocol . Need prolonged bedrest major surgery Smokers age 35 old NNRTIs within 30 day study entry Nausea , vomiting , abdominal pain Grade 3 high within 30 day study entry Known allergy sensitivity ethinyl estradiol ( EE ) , norelgestromin ( NGMN ) , component Ortho Evra contraceptive patch Known allergy sensitivity norethindrone component ON 1/35 oral contraceptive pill Serious illness require systemic treatment hospitalization within 14 day study entry Undiagnosed abnormal vaginal bleeding DepoProvera ( medroxyprogesterone acetate ) within 180 day study entry Lunelle ( estradiol cypionate medroxyprogesterone acetate ) within 90 day study entry Use certain medication within 30 day study entry Current drug alcohol use dependence , opinion investigator , may interfere study Unable adhere HAART , Ortho Evra contraceptive patch , single dose ON 1/35 regimen</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Birth Control Pills</keyword>
	<keyword>Oral Contraceptives</keyword>
	<keyword>Contraceptive Patch</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Antiretroviral Therapy , Highly Active</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>Contraception</keyword>
</DOC>